ArticleJournal of fish biology2026
Effects of dietary chitosan oligosaccharide on juvenile grass carp: Insight from the intestinal microbiota and metabolism.
Article in Journal of fish biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Nowadays, chitosan oligosaccharide (COS) served as a feed additive has been gradually applied to aquaculture. In aims to reveal the effects of COS on the growth intestinal microbiota and metabolism of Grass carp, this experiment using the feed with 3% COS supplement was conducted. The results indicated that the growth indicators (WGR and SGR) of Grass carp were promoted significantly (p < 0.05). Moreover, the non-specific immunity in the liver of carp increased owing to the rising LZM activity by the effect of COS. Meanwhile, the intestinal microbiota diversity indices declined and the dominance rose on account of COS. In addition, the intestinal health of Grass carp was improved greatly, reflecting in the 5.48 times higher level of '(Fusobacteriota+Firmicutes+Bacteroidota)/Proteobacteria' compared to the control. Furthermore, the genus of Cetobacterium, Plesiomonas and Brevinema were enriched in the COS treatment, and the intestinal microbiota profile was improved through increasing the abundance of beneficial bacteria (Cetobacterium). Besides, a series of lysophosphatidylcholine (LPC) (LPC 16:2, LPC 14:0, LPC 19:2, LPC 19:1, LPC O-16:2), lysophosphatidylethanolamine (LPE) (LPE 16:2 and LPE O-16:2) and a butanoic acid derivative named 3-[4-methyl-1-(2-methylpropanoyl)-3-oxocyclohexyl]butanoic acid were up-regulated, and two long chain fatty acyl-CoA (LPG) (LPG 20:2 and LPG 18:0) and LPS 20:3 belonging to lipopolysaccharide (LPS) down-regulated in the COS treatment. Therefore the result implied that the intestinal health of Grass carp would be protected via reducing the LPS induced the intestinal oxidative stress and inflammatory injury in fish. The metabolic pathways enriched in the profile between the COS treatment and control were mainly concentrated on lipid and derivative metabolism, amino acid metabolism, carbohydrate metabolism and ones associated to the signal transduction. Based on the correlation analysis, butanoic acid was identified as the metabolic marker related to Cetobacterium and Plesiomonas, while LPC O-16:2 was determined as the biomarker associated to Brevinema. Therefore, the application of COS gives promising results and will be a green feed additive in aquaculture.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.